ArticleJournal of neurology2026
Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned.Neurological research and practice · 2026Review
- Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center.Clinical parkinsonism & related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion is an emerging device-aided therapy for advanced Parkinson's disease (PD), but real-world evidence on multidomain outcomes and treatment persistence remains limited.
methodsConsecutive patients starting LDp/CDp at seven centers were followed for 6 months. Outcomes were the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39). Longitudinal changes were analyzed using linear mixed-effects models with false discovery rate (FDR) correction. Treatment discontinuation was evaluated using Kaplan-Meier estimates and Cox proportional hazards models, with sensitivity and exploratory analyses.
resultsWe enrolled 108 patients (mean age 64.7 years; mean disease duration 12.9 years). After FDR correction, MDS-UPDRS Parts I and IV improved at 3 and 6 months; Part II improved at 3 months only, and Part III showed no clear change. PDQ-39 was largely unchanged except for significant improvement in bodily discomfort at 3 months. Forty-three patients (39.8%) discontinued LDp/CDp mostly within 90 days, primarily due to insufficient efficacy or adverse events. Longer disease duration was associated with discontinuation in the core multivariable Cox model (HR 1.11 per year, 95% CI 1.04-1.18, p < 0.001), with similar results in sensitivity analyses. Exploratory analyses showed a suggestive association between PDQ-39 Summary Index and discontinuation, with domain-level associations for emotional well-being, stigma, social support, and cognition.
conclusionsIn routine care, LDp/CDp was associated with improvements across several MDS-UPDRS domains, although early discontinuation was common. Baseline disease duration and patient-reported quality-of-life dimensions may help identify support needs during the early initiation phase.
Indexed as
Identifiers
42154082What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.